Moderate to Severe Crohn's Disease Clinical Trial
Official title:
A Phase I/IIa, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NI-0401 in Patients With Moderate to Severe Active Crohn´s Disease
The purpose of the study is to assess the safety and tolerability of daily intravenous NI-0401 treatment, compared to matching placebo. And to assess the ability of NI-0401 to modulate the CD3 complex on T-cells.
n/a
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02148718 -
Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease
|
Phase 4 | |
| Not yet recruiting |
NCT06450197 -
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
|
Phase 2 |